Related Experiment Video

Updated: Jan 18, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

470

Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with

Xue Tang1, Lingying Zhao2, Wujiao Li2

  • 1Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen.

Haematologica
|September 11, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

581
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

470
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

581
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

Articles linked to this work by shared authors, journal, and citation graph.

Amine-Structure-Regulated Vanillin-Derived Imine-Cross-Linked Networks for Reprocessable, Self-Healing, and Chemically Recyclable Thermosets.

ACS omega·2026

Fusion-specific co-mutational architecture and treatment-response associations in pediatric core-binding factor acute myeloid leukemia: a multicenter exome-profiled cohort.

Frontiers in oncology·2026

Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers.

Pediatric blood & cancer·2026

Multidisciplinary management of fractures in patients with hemophilia: Advances in perioperative hemostasis and functional restoration in the era of novel therapies.

Injury·2026

Synergistic Catalysis of Single-Atom Alloys and Ordered Indium Clusters in Aluminum Sheet for Enhanced Hydrogen Production.

Advanced materials (Deerfield Beach, Fla.)·2026

Effector FsSCR6 contributes to the virulence of Fusarium sacchari on sugarcane and suppresses plant immunity.

Plant physiology and biochemistry : PPB·2026

Early measurement of ST2 and REG3α has a prognostic impact in haploidentical transplantation with post-transplant cyclophosphamide.

Haematologica·2026

The double-edged sword of Plasmodium falciparum: malaria and a predisposition to B-cell malignancy?

Haematologica·2026

Venetoclax plus azacitidine in younger adults with acute myeloid leukemia beyond historical comparisons. Comment on: "Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy".

Haematologica·2026

Beyond exclusion: the case for genetic screening in immune thrombocytopenia.

Haematologica·2026

Hyperinflammatory differentiation syndrome with hemophagocytic lymphohistiocytosis-like features following menin inhibition in acute myeloid leukemia.

Haematologica·2026

Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE study.

Haematologica·2026

Severe perioperative immune-related adverse events requiring intensive care in patients with gastric cancer: a case series.

Journal of medical case reports·2026

Ileorectal fistula after resection of perforated sigmoid tumor and Hartmann's procedure with uterine invasion: a case report.

Journal of medical case reports·2026

[Intravenous Thrombolysis for Acute Ischemic Stroke: Current Evidence and Perspectives].

No shinkei geka. Neurological surgery·2026

Maternal immunoglobulin G anti-A and anti-B antibody titres for predicting neonatal immune sensitisation in ABO-incompatible pregnancies: The Maternal Anti-A and Anti-B Antibody Titres in ABO-Incompatible Pregnancies study.

Vox sanguinis·2026

The Effectiveness of Emotion Regulation-Based Therapy on Emotion Regulation, Cognitive Flexibility, and Symptom Severity in Patients with Irritable Bowel Syndrome.

Clinics and research in hepatology and gastroenterology·2026

Mechanistic basis for the selective recognition of the Fcγ receptor IIa by monoclonal antibody IV.3.

Journal of structural biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us